Literature DB >> 28371032

Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.

M Carcao1, S Kearney2, E Santagostino3, J O O Oyesiku4, N L Young5, J Meunier6, C S Hoxer7, C Zhang1, V S Blanchette1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28371032     DOI： 10.1111/hae.13195

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  3 in total

1.  Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP.

Authors:  Sylvia von Mackensen; Jinesh Shah; Wilfried Seifert; Gili Kenet
Journal:  Haemophilia       Date:  2018-11-14       Impact factor: 4.287

2.  Recombinant factor IX-Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life.

Authors:  Mairead O'Donovan; Eimear Quinn; Kate Johnston; Evelyn Singleton; Julie Benson; Brian O'Mahony; Declan Noone; Cleona Duggan; Ruth Gilmore; Kevin Ryan; James S O'Donnell; Niamh M O'Connell; Johnny Mahlangu
Journal:  Res Pract Thromb Haemost       Date:  2021-10-11

Review 3.  Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B.

Authors:  Johnny N Mahlangu
Journal:  Ther Adv Hematol       Date:  2018-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.